Illumina, Inc. (NASDAQ:ILMN) has earned a consensus rating of “Buy” from the seventeen brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $354.35.
Several research firms have recently commented on ILMN. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Tuesday. Canaccord Genuity restated a “buy” rating and set a $360.00 target price (up previously from $350.00) on shares of Illumina in a research report on Monday. Wolfe Research began coverage on shares of Illumina in a research report on Thursday, May 30th. They set an “outperform” rating on the stock. OTR Global lowered shares of Illumina to a “positive” rating in a research report on Tuesday, April 2nd. Finally, Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, March 27th.
In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $306.93, for a total transaction of $1,012,869.00. Following the transaction, the director now owns 338,268 shares of the company’s stock, valued at $103,824,597.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Omead Ostadan sold 1,260 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $335.03, for a total transaction of $422,137.80. Following the transaction, the senior vice president now directly owns 11,945 shares in the company, valued at approximately $4,001,933.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,991 shares of company stock worth $14,643,684. 0.38% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the business. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 83.0% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 39 shares during the period. Strategy Asset Managers LLC purchased a new position in shares of Illumina in the 1st quarter valued at $26,000. Financial Advocates Investment Management raised its stake in shares of Illumina by 1,430.0% in the 4th quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 572 shares during the period. Proficio Capital Partners LLC raised its stake in shares of Illumina by 61.7% in the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Finally, C J Advisory Inc purchased a new position in shares of Illumina in the 1st quarter valued at $29,000. 89.73% of the stock is currently owned by institutional investors.
ILMN stock opened at $341.28 on Tuesday. The company has a market capitalization of $50.08 billion, a PE ratio of 59.66, a price-to-earnings-growth ratio of 2.34 and a beta of 1.07. Illumina has a 12 month low of $268.62 and a 12 month high of $372.61. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.34 by $0.26. The business had revenue of $846.00 million for the quarter, compared to analyst estimates of $838.70 million. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.45 earnings per share. Equities analysts anticipate that Illumina will post 6.68 EPS for the current fiscal year.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Do equity income investments outperform growth and income investments?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.